Immungenetics AG

What Immungenetics AG does

Immungenetics AG is a privately held, clinical-stage biopharmaceutical company headquartered in Hamburg, Germany, with a secondary office at BioLabs Heidelberg. Founded in 2009 and operating with 11-50 employees, the company is organized as a venture builder that funds early-stage research, advances candidates through early clinical trials, and intends to monetize through spin-outs, joint ventures, and out-licensing to life science partners. Its scientific activity spans five therapeutic verticals: neurodegenerative diseases, mitochondrial dysfunctions, autoimmune and inflammatory diseases, metabolic syndromes, and longevity.

The company's core assets are described as molecular science platforms rather than named drug candidates, and no specific platform names, patents, or development-stage assets are disclosed in available material. It reports three customer segments — investors, research institutions, and life science/pharma partners — and 12 cooperation partners plus 4 supporters are visible on its website, though none are individually named. The website also references a "global go-to-market" via partnerships and licensing, but no deals, milestones, or royalty arrangements have been disclosed.

Revenue is generated, in principle, from licensing and royalties and from professional services tied to early-stage clinical trial execution. No revenue figures, funding rounds, or M&A activity are disclosed. Leadership consists of co-CEOs Jonas Fischer and Max Brattig, Chairman Dr. Tilman Fischer, and board members Edward Capel-Cure and Michael Messemer. No AI/ML capabilities, data assets, or computational platforms are referenced.

Name

Immungenetics AG

Legal name

Immungenetics AG

Website

https://immungenetics.com

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

11–50 employees

Short description

Immungenetics AG is a privately held, Hamburg-based clinical-stage biopharmaceutical venture builder that funds early-stage research across neurodegeneration, mitochondrial dysfunction, autoimmune/inflammatory, metabolic, and longevity indications, advancing assets through early clinical trials for spin-out, joint venture, or out-licensing to life science partners.

Ownership category

akta.pro rank

Product category

Early-Stage Biopharmaceutical R&D and IP Licensing

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834)

akta.pro primary industry

Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)

akta.pro secondary industry

Immunology & Inflammation Pharmaceuticals (HLAIAAAD)

Keywords

• Biopharmaceutical research
• Early-stage therapeutics
• Neurodegenerative drug discovery
• Longevity research
• Scientific IP licensing

Headquarters

HQ city

Hamburg

HQ country

Germany

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure

Revenue model

1. Spin-out and Licensing: The company develops scientific programs and intellectual property that are prepared for spin-out, licensing, or partnership arrangements with downstream pharmaceutical or biotech companies.
2. Joint Ventures and Out-licensing: Enabling spin-outs, joint ventures, and out-licensing models to generate returns from developed scientific platforms and programs.
3. Early-Stage Clinical Trials: Conducting early-stage clinical trials as part of their scientific development activities, potentially leading to partnership or licensing opportunities.

Distribution channels1 record

Marketing channels1 record

Core offering

Immungenetics AG is a specialized research company that finances and structures early-stage scientific breakthroughs, develops high-quality intellectual property, and prepares scientific programs for spin-out, licensing, or partnership with downstream pharmaceutical or biotech companies. It funds foundational research, conducts early-stage clinical trials, and enables spin-outs, joint ventures, and out-licensing models focused on scientific platforms in neurodegenerative diseases, mitochondrial dysfunctions, autoimmune and inflammatory diseases, metabolic syndromes and diabetes, and longevity.

Product overview

Immungenetics AG operates as a specialized research and development company focused on financing and structuring early-stage scientific breakthroughs in therapeutic areas including neurodegenerative diseases, mitochondrial dysfunctions, autoimmune and inflammatory diseases, metabolic syndromes and diabetes, and longevity. The company does not offer discrete named products but rather functions as a scientific and strategic enabler that funds foundational research, develops intellectual property, conducts early-stage clinical trials, and enables spin-outs, joint ventures, and out-licensing models. The company's focus is on scientific platforms rather than single-asset development.

Differentiator

Problem solved

Functional benefit

Products and services

• Scientific Platform Development and IP Licensing Funding and development of early-stage scientific platforms and associated intellectual property in neurodegenerative diseases, mitochondrial dysfunctions, autoimmune and inflammatory diseases, metabolic syndromes and diabetes, and longevity, prepared for downstream spin-out, licensing, or partnership transactions.
• Early-Stage Clinical Trial Services Execution of early-stage clinical trials to validate therapeutic potential of the company's scientific platforms and create the supporting evidence base for downstream spin-outs, joint ventures, and out-licensing deals with pharma and biotech partners.
• Spin-Out and Joint Venture Enablement Structured enablement of new venture formations and joint ventures around validated scientific programs, allowing investors and pharma partners to participate in the commercial translation of the company's research platforms.

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves5 records

Expansion highlights5 records

Broad incumbents

• BioNTech SE: German biotechnology company that develops immunotherapies and platforms for cancer, infectious diseases, and other conditions, headquartered near Mainz. Comparable as a Germany-based biotech platform company with autoimmune/inflammation adjacency, though at vastly larger scale.
• MorphoSys AG: Established German biopharmaceutical company developing therapeutics in oncology, autoimmune and inflammatory diseases with a focus on antibody-based drug discovery. Comparable in therapeutic focus area and German base, though at a much larger scale.

Emerging players

• Athira Pharma: Clinical-stage biopharmaceutical company developing small molecules designed to modulate neurotrophic pathways for neurodegenerative diseases including Alzheimer's and Parkinson's. Directly comparable therapeutic focus on neurodegenerative indications.
• Cyclerion Therapeutics: Clinical-stage biopharmaceutical company developing treatments for serious diseases with prior focus on mitochondrial and CNS-related indications. Overlaps with Immungenetics' mitochondrial dysfunction and neurodegenerative focus areas.
• BioAge Labs: Clinical-stage biotechnology company developing therapeutics that target the biology of aging and age-related diseases including metabolic dysfunction. Comparable focus on longevity and metabolic syndrome indications.
• Longeveron Inc: Clinical-stage biotechnology company developing cellular therapies for aging-related and life-threatening conditions, with an explicit focus on healthy aging and longevity. Comparable longevity therapeutic focus.
• Cassava Sciences: Clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases including Alzheimer's disease. Comparable early clinical-stage focus on neurodegenerative therapeutic development.
• Cardior Pharmaceuticals: Germany-based clinical-stage biotech developing RNA-based therapeutics for cardiovascular and metabolic diseases. Comparable as a German clinical-stage platform biotech with therapeutic development focus.

Direct peers

• Evotec SE: German biotech platform company based in Hamburg that operates a research and development platform partnering with pharma on early-stage drug discovery and development. Comparable business model of platform-based early-stage therapeutic development with similar geographic base.
• MetrioPharm AG: Clinical-stage European biopharmaceutical company developing small-molecule immunomodulators for autoimmune and inflammatory diseases. Comparable focus on inflammation/autoimmune therapeutics with a similar early clinical-stage profile.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/immungenetics-ag

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Immungenetics AG